Open Journal Systems

The correlation between osteopontin level and radiation response of malignant gliomas at Cipto Mangunkusumo Hospital

Isnaniah Hasan ()
Sri Mutya Sekarutami ()
Renindra A. Aman ()
Nurjati C. Siregar ()
Rahmad Mulyadi ()


Osteopontin is an endogenous molecular marker for tumor hypoxia, and hypoxia is one of the factors that determine the aggressiveness of the disease. The purpose of this study is to determine the correlation between osteopontin levels and radiation response in malignant glioma. A retrospective cohort study was conducted on 15 malignant glioma patients who underwent radiation therapy from July 2004 to May 2015 at the RSUPN Dr. Cipto Mangunkusumo Hospital. Osteopontin levels were measured from paraffin-embedded tissue using a commercial ELISA kit. Tumor volume was calculated using computed tomography (CT) scan and magnetic resonance imaging (MRI) images, based on three-dimensional volume measurements. Tumor response was evaluated by comparing pre- and post-radiation tumor volumes using CT scan and MRI images. The mean osteopontin level was 0.49 ± 0.45 ng/mL and the mean percentage change in tumor volume was 8.59 ± 54.22%, with a 60% enlargement in tumor volume. A progressive disease was found in 26.7% of patients. There was a weak but insignificant negative correlation (r = -0.39, p = 0.146) between the level of osteopontin and radiation response. In contrast, there was a strong but insignificant positive correlation (= +0.68, p = 0.219) between the level of osteopontin and radiation response in the patient group that used the chemosensitizer temozolamide.


osteopontin; malignant glioma; radiation response

Full Text:



Central brain tumor registry of the United States (CBTR-US)[Internet]. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004–2008; 2012 February [updated 2012 March 23; cited 2015 July 15]. Available from:

Noda S, Jawahri A, Patel D, Lautenschlaeger T, Siedow M. Molecular advances of brain tumors in radiation oncology.Semin Radiat Oncol 2009; 19(3): 171–178. doi: 10.1016/j.semradonc.2009.02.005.

Watkins S, Sontheimer H. Unique biology of gliomas: Challenges and opportunities. Trends Neurosci 2012; 35(9): 546–556. doi: 10.1016/j.tins.2012.05.001.

Yoshimura M, Itasaka S, Harada H, Hiraoka M. Micro-environment and radiation therapy. Biomed Res Int 2013; 2013: 1–13. doi: 10.1155/2013/685308.

Zhao M, Xu H, Liang F, He J, Zhang J. Association of osteopontin expression with the prognosis of glioma patient: A meta-analysis. Tumor Biol 2014; 36(1): 429– 436. doi: 10.1007/s13277-014-2645-y.

Said HM, Hagemann C, Staab A, Stojic J, Vince GH, et al. Expression patterns of the hypoxia-related genes osteopontin, CA9, erythropoietin, VEGF and HIF-1 a in human glioma in vitro and in vivo. Radiother Oncol 2007; 83(3): 398–405. doi: 10.1016/j.radonc.2007.05.003.

Said HM, Katzer A, Flentje M, Vordermark D. Response of the plasma hypoxia marker osteopontin to in vitro hypoxia in human tumor cells. Radiother Biol 2005; 76(2): 200–205. doi: 10.1016/j.radonc.2005.06.023.

Jan H, Lee C, Shih Y, Hueng D, Ma H, et al. Osteopontin regulates human glioma cell invasiveness and tumor growth in mice. Neuro-Oncol 2010; 12(1): 58–70. doi: 10.1093/neuonc/nop013.

Denhardt DT, Noda M, O’ Regan AW, Pavlin D, Berman JS. Osteopontin as a means to cope with environmental insults: Regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest. 2001 May 1; 107(9): 1055–1061. doi: 10.1172/JCI12980.

Rodrigues LR, Teixeira JA, Schmitt FL, Paulsson M, Lindmark-Mänsson H. The role of osteopontin in tumor progression and metastasis in breast cancer. Cancer Epidemiol Biomarkers Prev 2007; 16(6): 1087–1097. doi: 10.1158/1055-9965.EPI-06-1008.

Renindra Ananda Aman. Identifikasi faktor prediksi radiosensitivitas tumor sel GLIA: Tinjauan khusus pada angiogenesis, proliferasi dan apoptosis sebagai perang-aibiologik tumor (Indonesian) [Identification of glia tumor cells’ radiosensitivity prediction factor: A study on ang¬io-genesis, proliferation, and apoptosis as the tum¬o-r’s biological characteristics]. Indonesian: Universitas Indonesia; 2008. p. 1–101.

Saitoh Y, Kuratsu J, Takeshima H, Yamamoto S, Ushio Y. Expression of osteopontin in human glioma. Its corr¬elation with the malignancy. Lab Invest 1995; 72(1): 55–63.

Mirna P, Soehartati AG, DiahRini H, Sahat M, Adang BK. Osteopontin level correlates negatively with tumor shri-nkage in neoadjuvant chemoradiation of locally adva¬nced rectal cancer. Adv Mod Oncol Res 2015; 1(1): 56-61. doi: 10.18282/amor.v1.i1.17.

van Rijn J, Hermans JJ, van den Berg, van der Valk P, Slotman BJ. Survival of human glioma cells treated with various combination of temozolamide and X-rays. Int J Radiat Oncol Biol Phys 2000; 47(3): 779–784. doi: 10.1016/S0360-3016(99)00539-8.

Wedge SR, Porteous JK, Glaser MG, Marcus K, Newl-ands ES. In vitro evaluation of temozolamide combined with X-irradiation. Anticancer Drug 1997; 8(1): 92–97.

Hirose Y, Berger MS, Pieper RO. p53 effects both the duration of G2/M arrest and the fate of temozolomide- treated human glioblastoma cells. Cancer Res 2001; 61(5): 1957–1963.

Wick W, Wick A, Schulz JB, Schulz B, Dichgans J, et al. Prevention of irradiation-induced glioma cell invasion by temozolomide involves Caspase 3 activity and cleavage of focal adhesion kinase. Cancer Res 2002; 62(6): 1915– 1919.

Chakravarti A, Erkkinen MG, Nestler U, Stupp R, Mehta M, et al. Temozolamide mediated radiation enhancement in glioblastoma: A report on underlying mechanisms. Clin Cancer Res 2006; 12(15): 4738–4746. doi: 10.1158/1078- 0432.CCR-06-0596.



  • There are currently no refbacks.

Copyright (c) 2018 Isnaniah Hasan, Sri Mutya Sekarutami, Renindra A. Aman, Nurjati C. Siregar, Rahmad Mulyadi

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.